PL
Pliant Therapeutics, Inc.
PLRX · NASDAQ
$1.11 -0.89% (-$0.01)
1M -2.63%
Market Cap $68.7M
P/E Ratio -
Div. Yield -
ROE 53.22%
Bulios Fair Price
$0.93
16.2% downside
Current Price
$1.11
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PLRX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.47x
P/FFO N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 16.69%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 53.22%
ROA 48.60%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 9.90x
Int. coverage -93.97x
Debt/Equity 0.20x
Stability
50 /100
Moderate EPS volatility 28.20%
Profitable years 0
Beta 1.28x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PLRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Bernard Coulie
Employees
49
Headquarters
South San Francisco
Upcoming events
05 NOV
Earnings
Upcoming earnings report